Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 8/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.33 |
| ▸ | STAMBP | O95630 | 1/20 | 0.33 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30776807 | 0.86 | MGAM (0.39) | PSMD14LMNAKDM4E | |
| SCHEMBL9995935 | 0.72 | NNMT (0.38) | NNMTHPGDSSMN1; SMN2PSMD14STAMBP | |
| SCHEMBL786065 | 0.71 | TSHR (0.53) | SMN1; SMN2TSHRCHEK2CHEK1 | |
| SCHEMBL30387165 | 0.71 | TSHR (0.53) | SMN1; SMN2TSHRCHEK2CHEK1 | |
| SCHEMBL28071109 | 0.70 | NNMT (0.42) | NNMTHPGDSSMN1; SMN2PSMD14STAMBP | |
| SCHEMBL29664524 | 0.69 | NPC1 (0.43) | NNMTHPGDSSMN1; SMN2TSHRCHEK2 | |
| SCHEMBL25787974 | 0.69 | TSHR (0.54) | NNMTHPGDSSMN1; SMN2TSHRCHEK2 | |
| SCHEMBL6282473 | 0.69 | NNMT (0.51) | NNMTHPGDSSMN1; SMN2PSMD14STAMBP | |
| SCHEMBL30427718 | 0.69 | NNMT (0.51) | NNMTHPGDSSMN1; SMN2PSMD14STAMBP | |
| SCHEMBL30445575 | 0.69 | NNMT (0.51) | NNMTHPGDSSMN1; SMN2PSMD14STAMBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-3665169-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019032863-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| EP-2970200-A1 | PYRIDINE CDK9 KINASE INHIBITORS | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160017-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | NNMT 703/4885HPGDS 2414/4885SMN1; SMN2 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.